Advertisement

Topics

Clovis Oncology Presents Results from Ongoing Phase 2 Study Evaluating Rubraca in Metastatic Castration Resistant Prostate Cancer

09:56 EDT 19 Oct 2018 | Speciality Pharma Journal

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology). The data show a 44% confirmed objective response rate (ORR) by investigator assessment in 25 RECIST* /PCWG3** response-evaluable patients with a BRCA1/2 alteration. The median duration of response in these …

Original Article: Clovis Oncology Presents Results from Ongoing Phase 2 Study Evaluating Rubraca in Metastatic Castration Resistant Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology Presents Results from Ongoing Phase 2 Study Evaluating Rubraca in Metastatic Castration Resistant Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...